×
Jyong Biotech Long Term Debt 1970-1969 | MENS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Jyong Biotech long term debt from 1970 to 1969. Long term debt can be defined as the sum of all long term debt fields.
View More
Jyong Biotech Long Term Debt 1970-1969 | MENS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Jyong Biotech long term debt from 1970 to 1969. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$225.3B
Amgen (AMGN)
$164.8B
Gilead Sciences (GILD)
$144.5B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$98.6B
CSL (CSLLY)
$85.4B
GSK (GSK)
$77.7B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$42.9B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.7B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.7B
Biogen (BIIB)
$19.3B
Illumina (ILMN)
$17.3B
Genmab (GMAB)
$15B
Genmab (GNMSF)
$15B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.4B
QIAGEN (QGEN)
$11.5B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Bio-Techne Corp (TECH)
$9.2B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8B
Roivant Sciences (ROIV)
$7.9B